{
    "name": "tesamorelin",
    "comment": "Rx",
    "other_names": [
        "Egrifta"
    ],
    "classes": [
        "Growth Hormone Releasing Factors"
    ],
    "source": "https://reference.medscape.com/drug/egrifta-tesamorelin-999613",
    "pregnancy": {
        "common": [
            "Contraindicated",
            "During pregnancy, visceral adipose tissue increases due to normal metabolic and hormonal changes; modifying this physiologic change offers no known benefit and could result in fetal harm",
            "Administration to rats during organogenesis and lactation resulted in hydrocephaly in offspring at 2-4 times clinical dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Centers for Disease Control and Prevention recommend that HIV-infected mothers in the United States not human milk-feed their infants to avoid risking postnatal transmission of HIV-1 infection",
            "Because of both the potential for HIV-1 infection transmission and serious adverse reactions in nursing infants, breastfeeding women should be instructed not to human milk-feed"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "tesamorelin will decrease the level or effect of cortisone by  altering metabolism. Avoid or Use Alternate Drug. Patients receiving glucocorticoid replacement therapy with cortisone may require increased doses; monitor for reduce effects of cortisone therapy"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "tesamorelin will decrease the level or effect of prednisone by  altering metabolism. Avoid or Use Alternate Drug. Patients receiving glucocorticoid replacement therapy with prednisone may require increased doses; monitor patients for reduced prednisone effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ulipristal",
            "description": {
                "common": "tesamorelin will decrease the level or effect of ulipristal by  altering metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "tesamorelin will decrease the level or effect of bazedoxifene/conjugated estrogens by  altering metabolism. Use Caution/Monitor. May decrease efficacy; monitor"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "tesamorelin will decrease the level or effect of carbamazepine by  altering metabolism. Modify Therapy/Monitor Closely. Monitor levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "tesamorelin will decrease the level or effect of conjugated estrogens by  altering metabolism. Use Caution/Monitor. May decrease efficacy; monitor"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "tesamorelin will decrease the level or effect of conjugated estrogens, vaginal by  altering metabolism. Use Caution/Monitor. May decrease efficacy; monitor"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazoxide",
            "description": {
                "common": "tesamorelin will decrease the level or effect of diazoxide by  altering metabolism. Modify Therapy/Monitor Closely. Monitor glucose levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol combos",
            "description": {
                "common": "tesamorelin will decrease the level or effect of estradiol combos by  altering metabolism. Use Caution/Monitor. Use alternative contraception"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "tesamorelin will decrease the level or effect of exenatide injectable solution by  altering metabolism. Modify Therapy/Monitor Closely. Monitor glucose levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "tesamorelin will decrease the level or effect of exenatide injectable suspension by  altering metabolism. Modify Therapy/Monitor Closely. Monitor glucose levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "tesamorelin will decrease the level or effect of irinotecan liposomal by  altering metabolism. Use Caution/Monitor. Avoid combo. Consider discontinuation of tesamelin at least 2 weeks before initiating irinotecan therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "tesamorelin will decrease the level or effect of levonorgestrel intrauterine by  altering metabolism. Use Caution/Monitor. Use alternative contraception"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "tesamorelin will decrease the level or effect of levonorgestrel oral by  altering metabolism. Use Caution/Monitor. Use alternative contraception"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "tesamorelin will decrease the level or effect of medroxyprogesterone by  altering metabolism. Use Caution/Monitor. Use alternative contraception"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norethindrone",
            "description": {
                "common": "tesamorelin will decrease the level or effect of norethindrone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use alternative contraception"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "tesamorelin will decrease the level or effect of phenytoin by  altering metabolism. Modify Therapy/Monitor Closely. Monitor levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "theophylline will decrease the level or effect of tesamorelin by  altering metabolism. Modify Therapy/Monitor Closely. Monitor theophylline levels"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Arthralgia",
            "percent": "13.3"
        },
        {
            "name": "Injection site reactions",
            "percent": "8.5"
        },
        {
            "name": "up to",
            "percent": "6.1"
        },
        {
            "name": "Extremity pain",
            "percent": "5.5"
        },
        {
            "name": "Myalgia",
            "percent": "4.8"
        },
        {
            "name": "Paresthesia",
            "percent": "4.4"
        },
        {
            "name": "Nausea",
            "percent": "4.2"
        },
        {
            "name": "Hypoesthesia",
            "percent": "3.7"
        },
        {
            "name": "Rash",
            "percent": "2.6"
        },
        {
            "name": "Vomiting",
            "percent": "2.4"
        },
        {
            "name": "Pruritus",
            "percent": "2"
        },
        {
            "name": "Depression",
            "percent": "1.7"
        },
        {
            "name": "Dyspepsia",
            "percent": "1.7-1.8"
        },
        {
            "name": "Musculoskeletal pain and stiffness",
            "percent": "1.5"
        },
        {
            "name": "Increased CPK",
            "percent": "1.5"
        },
        {
            "name": "Carpal tunnel syndrome",
            "percent": "1.1-1.5"
        },
        {
            "name": "Joint stiffness",
            "percent": "1.3"
        },
        {
            "name": "swelling",
            "percent": "1.1"
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Muscle spasms",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Abdominal abscess",
            "percent": null
        },
        {
            "name": "Cerebellar syndrome",
            "percent": null
        },
        {
            "name": "Mental status changes",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Trigeminal neuralgia",
            "percent": null
        },
        {
            "name": "Viral bronchitis",
            "percent": null
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": null
        }
    ]
}